Literature DB >> 34310559

A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.

Gurchetan Randhawa1, Sean Hagaman1, Mahsa Pourabdollah Tootkaboni1, Sanchit V Kundal1, Sharad Oli1, James Alrassi2,3, Sam D Schild2,3, Sara Abu-Ghanem2,3, Shelly Brejt1.   

Abstract

BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of dexamethasone. The purpose is to highlight this atypical presentation of a rare disease. CASE REPORT A 74-year-old woman with a medical history of diabetes mellitus (DM), hypertension, hyperlipidemia, and small cell lung cancer with metastasis to the brain presented to the Emergency Department with altered mental status and a hyperosmolar hyperglycemic state. Three weeks before, she had been diagnosed with DM (hemoglobin A1c [HbA1c] 6.5%) and was started on dexamethasone to treat cerebral edema. On admission, her HbA1c was 10.8%, although she had received only a short course of dexamethasone. Her physical exam was concerning for left eyelid swelling and ophthalmoplegia. Computed tomography of the head and neck revealed signs of left ocular proptosis and invasive rhinomaxillary fungal disease. The patient underwent urgent surgical debridement; subsequent magnetic resonance imaging revealed extensive fungal disease extending into her left inferior frontal lobe. A surgical pathology report was positive for Rhizopus oryzae and Stenotrophomonas maltophilia. Her blood cultures were positive for methicillin-susceptible Staphylococcus aureus. She was treated with antibiotics and amphotericin B. Her clinical course was complicated by hypokalemia. She eventually recovered and was discharged from the hospital. CONCLUSIONS This case highlights an atypical presentation of mucormycosis. Clinicians should remain vigilant for this rare complication of dexamethasone use even when the therapy is given for a short time.

Entities:  

Year:  2021        PMID: 34310559     DOI: 10.12659/AJCR.932129

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


  2 in total

1.  Successful treatment of rhino-cerebral mucormycosis with dual antifungal therapy and minimal surgical debridement.

Authors:  Lauren Bougioukas; Cindy D Noyes; Katherine Peterson; Lindsay M Smith; Andrew J Hale
Journal:  IDCases       Date:  2022-09-06

Review 2.  Resolving the equation between mucormycosis and COVID-19 disease.

Authors:  Ritu Pasrija; Mohammad Naime
Journal:  Mol Biol Rep       Date:  2022-01-22       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.